Study #2021-0582
A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)
MD Anderson Study Status
Enrolling
Treatment Agent
Enfortumab vedotin
Description
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Study phase:
Phase I
Physician name:
Ashish Kamat
Department:
Urology
For general questions about clinical trials:
1-844-705-0985
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.